- Home
- STAI vs NXL Comparison
STAI vs NXL Comparison
Compare STAI & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAI
- NXL
- Stock Information
- Founded
- STAI 2011
- NXL 2010
- Country
- STAI United States
- NXL United States
- Employees
- STAI N/A
- NXL N/A
- Industry
- STAI
- NXL Medical Specialities
- Sector
- STAI
- NXL Health Care
- Exchange
- STAI Nasdaq
- NXL Nasdaq
- Market Cap
- STAI 24.6M
- NXL 28.0M
- IPO Year
- STAI N/A
- NXL 2022
- Fundamental
- Price
- STAI $0.50
- NXL $1.50
- Analyst Decision
- STAI
- NXL Strong Buy
- Analyst Count
- STAI 0
- NXL 1
- Target Price
- STAI N/A
- NXL $5.00
- AVG Volume (30 Days)
- STAI 14.9M
- NXL 10.6M
- Earning Date
- STAI 09-17-2025
- NXL 11-07-2025
- Dividend Yield
- STAI N/A
- NXL N/A
- EPS Growth
- STAI N/A
- NXL N/A
- EPS
- STAI N/A
- NXL N/A
- Revenue
- STAI $1,249,524.00
- NXL $174,813.00
- Revenue This Year
- STAI N/A
- NXL $38.28
- Revenue Next Year
- STAI N/A
- NXL $185.71
- P/E Ratio
- STAI N/A
- NXL N/A
- Revenue Growth
- STAI 139.30
- NXL 16.42
- 52 Week Low
- STAI $0.35
- NXL $0.70
- 52 Week High
- STAI $9.07
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- STAI 48.16
- NXL 57.71
- Support Level
- STAI $0.48
- NXL $1.44
- Resistance Level
- STAI $0.73
- NXL $1.65
- Average True Range (ATR)
- STAI 0.07
- NXL 0.15
- MACD
- STAI -0.01
- NXL -0.01
- Stochastic Oscillator
- STAI 8.74
- NXL 55.81
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.